아포몰핀하이드로클로라이드

4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-

HCID 9410CAS 314-19-2

기본 정보

표준 SMILES
CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl
InChIKey
SKYZYDSNJIOXRL-BTQNPOSSSA-N
분자식
C17H18ClNO2
평균 분자량
303.8 g/mol
단동위원소 질량
303.1026065

이름 및 식별자

우선 이름
4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-
IUPAC
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride
현지명
아포몰핀하이드로클로라이드
영어명
Apomorphine hydrochloride
분자식
C17H18ClNO2
분자량
303.78

이름 및 동의어

(-)-Apomorphine hydrochloride4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-RefChem:527368314-19-2(R)-(-)-Apomorphine hydrochlorideApomorphine chlorideApomorphinium chlorideApomorphine hydrochloride anhydrous(-)-Apomorphine (hydrochloride)9K13MD7A0DApomorphine.HCl
이름 더 보기
아포몰핀하이드로클로라이드APOMORPHINE HCLAPL-130277(?)-Apomorphine(r)-idUPRIMATAK251)KW-6500R(–)-APONSC 11442APL130277
R-(-)-Apomorphine hydrochlorideApomorphine SLBritajectNSC-11442Apomorphin hydrochloridpomorphini hydrochloridumApomorphinum hydrochloricum(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride

데이터베이스 식별자

CAS
314-19-2
PubChem CID
9410
DTXSID
DTXSID5040598
UNII
9K13MD7A0D

물성

구조 계산 물성

극성 표면적
43.7 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
3
회전 가능 결합 수
0
무거운 원자 수
21

실험 및 물리화학적 성질

Collision Cross Section161.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
250 ℃ · >250℃
저장 조건
Store at RT
용해도
1.08 mg/mL · ≥1.08 mg/mL in EtOH with ultrasonic; ≥12.9 mg/mL in DMSO; ≥5.12 mg/mL in H2O
물리적 상태
고체
EPA
Apomorphine hydrochloride (314-19-2)

안전 및 규제

유해성 정보

Other Safety Information · 1건

IMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Environment tier I assessment;IMAP assessments - 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-: Human health tier I assessment

안전 데이터

tsca
TSCA listed
ridadr
3249
독성
mmo-sat 20 mg/plate MUREAV 137,17,84
포장분류
III
위험 등급
6.1(b)

화학 및 산업

용도 및 제조

General Manufacturing Information4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-: INACTIVE
응용 분야 · 2건

용도Emetic.

일반 설명Apomorphine hydrochloride,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolone-10,11-diol hydrochloride (Apokyn), is awhite or off-white powder or crystal soluble in hot water(pKa=8.92). Apormorphine is an aporphine alkaloid of thebenzoquinoline class. Oral apomorphine is poorly absorbedand has a bioavailability of less than 4%. Upon subcutaneousadministration, apomorphine is completely absorbed. Within10 to 20 minutes, the maximum concentration of the drug isdistributed from the blood plasma to the CSF. Other potentialroutes of administration include continuous subcutaneous infusion,intravenous infusion, intranasal spray application,sublingual, and rectal administration.23 The agent is highlylipophilic in nature, allowing for rapid diffusion across theBBB after injection. Apomorphine has a short plasma halflife;however, clinical effects may last from 60 to 90 minutes.Apomorphine displays a significant degree of interpatientvariability in its pharmacokinetic profile. Studies of bothintravenous and subcutaneous injection routes found this variation was not attributable to body weight, age, gender,and duration of PD or L-DOPA dose/duration alone.Apomorphine is extensively metabolized. Hypothesizedroutes include sulfation, N-demethylation, glucuronidation,and oxidation. Subcutaneous injections of apomorphine arerenally and hepatically cleared, with the majority appearingto be renally cleared. Dosage adjustments are needed in bothliver and renal impairment. The activity of apomorphine isbelieved to be caused by stimulation of postsynaptic D1- andD2-type receptors within the caudate/putamen in the brain.Apomorphine is indicated for the acute, intermittent treatmentof hypomobility, “off” episodes (“end-of-dose wearingoff” and unpredictable on/off episodes) associated with advancedPD.

상·하류 제품 정보

상류 원료

공급사17 곳

上海优宁维生物科技股份有限公司15921930842 15921930842 · [email protected]
武汉易泰科技有限公司上海分公司18930552037 · [email protected]
安耐吉化学&3A(安徽泽升科技有限公司)021-58432009 400-005-6266 · [email protected]
InvivoChem中国13549236410 · [email protected]
MedBio脉铂医药021-69568360 18916172912 · [email protected]

관련 반응

5건

연결된 노트

불러오는 중…